Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Ben-Gurion University of the Negev Research and Development Authority

Hadasit Medical Research Services and Development Ltd.

University of Rijeka Faculty of Medicine

University of Rueka Faculty of Medicine Rijeka, Croatia

Nectin Therapeutics Ltd.

Ofer Mandelboim

Stipan Jonjic

Pinchas Tsukerman

Angel Porgador

Noa S Kaynan

Chamutal Gur

Yaakov Naparstek

Gilad Benjamin Bachrach

Ariella Glasner

Adi Reches

Vladimir Yutkin

Orit Berhani

Natural killer (NK) cell killing of various tumors is inhibited in the presence of ligands of TIGIT, an inhibitory receptor present on all human NK cells and on various T cells. Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions comprising them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.

Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT)

The present invention provides monoclonal antibodies that recognize human Nectin4 with high affinity and specificity and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy and in diagnosis.

Antibodies specific to human NECTIN4

Monoclonal antibodies that recognize TIGIT and inhibit its suppressive activity on T-cells are provided as well as pharmaceutical compositions including them and methods for their use in cancer immunotherapy and in diagnosis and treatment of immune disorders.

Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)

The present invention provides attenuated or inactivated pathogenic bacteria having anti-cancer properties, compositions comprising the bacteria, and use thereof for treating cancers of the urogenital system.

Attenuated or inactivated pathogenicfor treating urogenital cancer

The present invention provides monoclonal antibodies that recognize polio virus receptor (PVR) and inhibit its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT). The present invention further provides pharmaceutical compositions comprising the antibodies and methods for their use in cancer immunotherapy, treating infections and in diagnosis.

Antibodies specific to human poliovirus receptor (PVR)

An affinity binding moiety comprising an antigen recognition region which comprises complementarity determining region (CDR) amino acid sequences as set forth in heavy chain ordered N to C terminus: SEQ ID NOs: 4, 6 and 8, and light chain ordered N to C terminus: SEQ ID NOs: 12, 14 and 16 is disclosed. A pharmaceutical compositions comprising as an active ingredient the affinity binding moiety is also disclosed. Methods of diagnosing, preventing or treating an autoimmune disease or a cancer associated with an expression of NKp46 are also disclosed.

Anti-NKP46 antibodies, toxin conjugates, and therapeutic use of same

The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.

Method of treating type 1 diabetes by administering NKp46 polypeptide

Method of treating diabetes by administering an anti-NKp46 antibody

The present invention relates generally to peptides derived from the natural cytotoxicity receptors on natural killer (NK) cells and to antibodies against peptide epitopes on these receptors. In particular, the present invention identifies an essential epitope in the proximal domain of NKp46 and NKp44 receptors present on NK cells, as a crucial element for the binding to viral-infected cells. The present invention provides peptides that are derived from the amino acid sequence of NKp46 receptor, capable of specific targeting of viral-infected cells and tumor cells and monoclonal antibodies which recognize a specific domain of NKp46. The present invention further provides hyperglycosylated peptides that are derived from the NKp44 receptor, capable of specific targeting of viral-infected cells.

Growing community of inventors

Shoham, Israel

Ofer Mandelboim